Afatinib showed significant activity in a phase II trial of patients with metastatic platinum-refractory urothelial carcinoma, and patients with HER2 or ERBB3 alterations had significantly better outcomes.
Combination therapy with bicalutamide and everolimus resulted in promising responses in a phase II trial of patients with castration-resistant prostate cancer, though a substantial proportion of patients experienced everolimus-related toxicities.
Results of a phase II randomized trial found that combining a short course of androgen deprivation therapy with bevacizumab improved relapse-free survival in men with hormone-sensitive prostate cancer.
Using simulation modeling, researchers found that PSA screening can be cost-effective if men with low-risk prostate cancer do not undergo treatment and if clinicians use restrictive criteria to make a decision to biopsy.
Dr. Morris discusses results and implications of the CHAARTED trial, which studied the survival impact of androgen deprivation therapy (ADT) plus docetaxel vs ADT alone for hormone-sensitive newly metastatic prostate cancer.
Dr. Bruce Roth, Professor of Oncology in the Division of Medicine at Siteman Cancer Center, Washington University at St. Louis, spoke at the 2013 ASCO meeting about topics in seminoma. Here he discusses the epidemiology of seminoma.